$60 million total is the largest corporate R&D investment at MIT
CAMBRIDGE, Mass., May 18, 2005 – DuPont Chief Technology Officer Thomas M. Connelly Jr. joined Massachusetts Institute of Technology (MIT) President Susan Hockfield and Provost Robert A. Brown today to announce continued funding of the DuPont MIT Alliance (DMA), a research program focused on creating innovative, next-generation materials.
Originally funded in 2000 as a five-year, $35 million investment, Connelly announced today that DuPont will contribute another $25 million to continue funding through 2010. This 10-year, $60 million commitment makes the DMA the largest corporate R&D investment at MIT.
"The successes and experiences of the Alliance warrant our continued funding," Connelly said. "In 2000, we asked MIT scientists to give us their best ideas on science that could enhance our everyday lives. The response and resulting research has led to significant scientific achievements. These first five years focused on inventing new materials using nature and biology as the design roadmap. The second stage of the Alliance will expand the collaborative capabilities of DuPont and MIT beyond bio-based science to also include nanocomposites, nanoelectronic materials, alternative energy technologies, and next generation safety and protection materials."
"Here at MIT, we are very proud of our long tradition of strong working relationships with world leaders in key industries. The DuPont MIT Alliance takes such partnerships to a new level, providing a model of successful university-industry collaboration not just for our two organizations, but nationally as well," said Susan Hockfield, MIT president. "The DuPont MIT Alliance is an example of academic-industry collaboration at its best, with MIT faculty and DuPont colleagues working together to define exciting research opportunities, to create wonderful new science and technology, and to educate graduate students in science and engineering in the midst of the excitement generated by the collaboration," said Robert A. Brown, MIT Provost.
Four top DMA research programs were showcased today to demonstrate the goals of the alliance: to advance basic science; to create commercial potential for novel scientific applications; or to develop enabling technologies that directly relate to the strategic direction of DuPont research and development. The featured MIT scientists and their programs were:
Professor Gregory Stephanopoulos: next-generation advances in metabolic engineering, including genome-wide analyses and modeling for the production of chemicals and intermediates from renewable bio-feedstocks; Professor Mriganka Sur, head of the Brain and Cognitive Sciences Dept.: an early stage research program to develop a novel biopolymer-based nervous system implant that could replace nonfunctional brain tissue following traumatic brain injury; Professor Linda Griffith, director of the Biotechnology Process Engineering Center: a device for tissue-like culturing of liver cells, designed to provide early assessment of the toxicity of new pharmaceuticals; Professor Michael Rubner, director of the Center for Material Science and Engineering: a novel material similar to the naturally water repellent surface of the lotus leaf. Potential applications include self-cleaning fabrics, water-repellant windshields, or plumbing that resists the growth of harmful bacteria by preventing water from accumulating on its surface.
Since its inception, the DuPont MIT Alliance has asked for proposals from the MIT community that draw upon the science, engineering and business expertise at MIT to extend DuPont's reach in the areas of biology, genetics, bioinformatics and catalysis. It has brought together the shared strengths of DuPont and MIT in materials and chemical and biological sciences to develop new materials and processes directed at bioelectronics, biosensors, biomimetic materials, alternative energy sources and new high-value materials. DMA also has provided an opportunity for DuPont to collaborate with MIT's Sloan School of Management to define new business models for these emerging technologies.
Source: Eurekalert & others
Published on PsychCentral.com. All rights reserved.
The aim of psychoanalysis is to relieve people of their neurotic unhappiness so that they can be normally unhappy.
-- Sigmund Freud